Bioprosthetic valve oversizing is associated with increased risk of valve thrombosis following TAVR.
aortic valve stenosis
bioprosthesis
thrombosis
transcatheter aortic valve replacement
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
15 02 2021
15 02 2021
Historique:
received:
12
05
2020
accepted:
07
06
2020
pubmed:
8
7
2020
medline:
25
9
2021
entrez:
8
7
2020
Statut:
ppublish
Résumé
Hypoattenuating leaflet thickening (HALT), the radiographic manifestation of transcatheter heart valve thrombosis, is commonly identified following transcatheter aortic valve replacement (TAVR) and associated with increased risk of stroke and structural valve deterioration. While anticoagulation effectively resolves HALT, routine use remains controversial. We aimed to identify hemodynamic, anatomic, and comorbid predictors of HALT. We evaluated consecutive patients with severe aortic stenosis who underwent TAVR with Edwards SAPIEN 3 bioprosthesis at a single center between June 1, 2018 and October 30, 2019. Patients on anticoagulation and those receiving valve-in-valve were excluded. Clinically driven computed tomography (CT) imaging was performed to assess for HALT at the discretion of the treating valve team. A total of 78 patients with a mean age of 78 ± 10 years and STS risk score 5.5 ± 3.3% were analyzed. HALT was identified in 11 (14.1%) patients. Compared to controls, those with HALT had smaller annular areas, 435 ± 57 mm In this pragmatic study of patients undergoing TAVR with SAPIEN 3 valves, we report the novel finding that oversizing by more than 20% was independently associated with increased risk of HALT. These findings warrant confirmation in larger and prospective trials.
Sections du résumé
BACKGROUND
Hypoattenuating leaflet thickening (HALT), the radiographic manifestation of transcatheter heart valve thrombosis, is commonly identified following transcatheter aortic valve replacement (TAVR) and associated with increased risk of stroke and structural valve deterioration. While anticoagulation effectively resolves HALT, routine use remains controversial. We aimed to identify hemodynamic, anatomic, and comorbid predictors of HALT.
METHODS
We evaluated consecutive patients with severe aortic stenosis who underwent TAVR with Edwards SAPIEN 3 bioprosthesis at a single center between June 1, 2018 and October 30, 2019. Patients on anticoagulation and those receiving valve-in-valve were excluded. Clinically driven computed tomography (CT) imaging was performed to assess for HALT at the discretion of the treating valve team.
RESULTS
A total of 78 patients with a mean age of 78 ± 10 years and STS risk score 5.5 ± 3.3% were analyzed. HALT was identified in 11 (14.1%) patients. Compared to controls, those with HALT had smaller annular areas, 435 ± 57 mm
CONCLUSIONS
In this pragmatic study of patients undergoing TAVR with SAPIEN 3 valves, we report the novel finding that oversizing by more than 20% was independently associated with increased risk of HALT. These findings warrant confirmation in larger and prospective trials.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
E411-E417Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the Management of Patients with Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2017;70(2):252-289.
Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739-2791.
Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363(17):1597-1607.
Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374(17):1609-1620.
Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695-1705.
Grover FL, Vemulapalli S, Carroll JD, et al. 2016 annual report of the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. JACC (J Am Coll Cardiol). 2016;69(10):1215-1230.
Kundi H, Strom JB, Valsdottir LR, et al. Trends in isolated surgical aortic valve replacement according to hospital-based Transcatheter aortic valve replacement volumes. J Am Coll Cardiol Intv. 2018;11(21):2148-2156.
Chakravarty T, Søndergaard L, Friedman J, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. The Lancet. 2017;389(10087):2383-2392.
Makkar RR, Fontana G, Jilaihawi H, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med. 2015;373(21):2015-2024.
Overtchouk P, Guedeney P, Rouanet S, et al. Long-term mortality and early valve dysfunction according to anticoagulation use: the France TAVI registry. J Am Coll Cardiol. 2019;73(1):13-21.
Dangas GD, Tijssen JGP, Wöhrle J, et al. A controlled trial of rivaroxaban after Transcatheter aortic-valve replacement. N Engl J Med. 2020;382(2):120-129.
Zamorano JL, Badano LP, Bruce C, et al. EAE/ASE recommendations for the use of echocardiography in new Transcatheter interventions for Valvular heart disease. J Am Soc Echocardiogr. 2011;24(9):937-965.
Yanagisawa R, Tanaka M, Yashima F, et al. Early and late leaflet thrombosis after Transcatheter aortic valve replacement: a multicenter initiative from the OCEAN-TAVI registry. Circ Cardiovasc Interv. 2019;12(2):e007349.
Yanagisawa R, Hayashida K, Yamada Y, et al. Incidence, predictors, and mid-term outcomes of possible leaflet thrombosis after TAVR. J Am Coll Cardiol Img. 2016;10(1):1-11.
Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence and sequelae of prosthesis-patient mismatch in transcatheter versus surgical valve replacement in high-risk patients with severe aortic stenosis: a PARTNER trial cohort-a analysis. J Am Coll Cardiol. 2014;64(13):1323-1334.
van der Boon RM, Nuis R, Van Mieghem NM, et al. New conduction abnormalities after TAVI-frequency and causes. Nat Rev Cardiol. 2012;9(8):454-463.
Blanke P, Reinöhl J, Schlensak C, et al. Prosthesis oversizing in balloon-expandable Transcatheter aortic valve implantation is associated with contained rupture of the aortic root. Circ Cardiovasc Interv. 2012;5(4):540-548.
Ducci A, Tzamtzis S, Mullen MJ, Burriesci G. Hemodynamics in the Valsalva sinuses after transcatheter aortic valve implantation (TAVI). J Heart Valve Dis. 2013;22(5):688.